Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Crohn’s disease, one major type of inflammatory bowel disease, has an incidence rate in the United States of approximately seven per 100,000. Advancing biotechnological knowledge regarding this idiopathic disease has led to the development of therapies aimed at specific targets in the disease pathway.

Drug Criteria & Outcomes: Off-label drug use: Etanercept (Enbrel) for Crohn’s disease?